43 results
Page 2 of 3
424B3
w11b w1seckt5x8ft103
16 Feb 22
Prospectus supplement
8:36am
8-K
EX-99.1
c69zzt2m6hq
16 Feb 22
Other Events
8:31am
424B3
24gso
18 Jan 22
Prospectus supplement
4:11pm
8-K
EX-99.1
r3yaj5hn0u65wtdk
18 Jan 22
Other Events
4:06pm
424B3
pesih2 gu
28 Dec 21
Prospectus supplement
4:05pm
8-K
EX-99.1
o50ewe8p ov7yrh
28 Dec 21
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML
4:01pm
8-K
EX-99.1
pviwqrcs79aaeh
12 Nov 21
Celularity Reports Third Quarter 2021 Financial Results and Corporate Update
4:19pm
8-K
EX-99.1
0f6t o40mywbmn
16 Aug 21
Celularity Reports Second Quarter 2021 Financial Results
5:20pm
424B3
7wzwrvo49hojjdbb
12 Aug 21
Prospectus supplement
4:21pm
8-K
EX-99.1
e1zxkcj8lc41ct6
22 Jul 21
Celularity Closes Merger with GX Acquisition Corp and Provides Corporate Update
4:13pm
425
but3s6vu4qnm y32
7 Jul 21
Business combination disclosure
4:11pm
425
i9rlx zpp42ase
1 Jul 21
Business combination disclosure
5:09pm
8-K
EX-99.1
hvyshxk
1 Jul 21
Celularity and Arthrex Enter into Exclusive Supply and Distribution Agreement for Multiple Commercial Products
5:07pm
424B3
brl2o
25 Jun 21
Prospectus supplement
12:48pm
S-4/A
s1uwf61p1
29 Mar 21
Registration of securities issued in business combination transactions (amended)
7:30am
S-4
gffdi1ed2bmndn vfmyc
25 Jan 21
Registration of securities issued in business combination transactions
4:51pm
8-K
EX-99.2
7k0ya
8 Jan 21
Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy
7:03am